Zacks Investment Research
02 Sept 2026, 14:51 UTC · 2w ago
Verdict
Headline takes no side. We score JNJ −0.60 across four claims — strongly bearish.
−0.60strongly bearish
More negative than 82% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The loss of exclusivity for Stelara reduced the growth of J&J's Innovative Medicines segment by 10.4% in 2025 and 8.4% in the first half of 2026.
So whatA significant drag on a primary revenue driver directly impacts top-line growth and profit margins.
More negative than 98% of claims this week
Johnson & Johnson expects generic competition for Simponi and Opsumit to weigh on sales throughout 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More negative than 91% of claims this week
Sales in J&J's Abiomed business declined 2% in Q2 due to slowing procedure volumes following a U.K. clinical trial that questioned the device's benefit.
More negative than 80% of claims this week
J&J continues to face investor concerns regarding lingering talc-related litigation and pricing pressure in key markets.
So whatOngoing legal liabilities create a persistent risk overhang and uncertainty for the stock's valuation.
More negative than 73% of claims this week
Which stocks this story touches
More negative than 82% of ticker scores this week
The company faces headwinds from major patent expirations for Stelara, pricing pressure, and ongoing talc-related litigation.
More positive than 65% of ticker scores this week
The company is benefiting from the launch of a biosimilar version of J&J's Stelara.
More positive than 65% of ticker scores this week
The company is benefiting from the launch of a biosimilar version of J&J's Stelara.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
12h ago
More positive than 56% of relationship scores this week
[mutual] Teva launched a biosimilar version of J&J's drug Stelara following its loss of patent exclusivity.
—
No price for JNJ right now — the quote feed didn't answer.
JNJ chart →
